L. Hansen Carl - 18 Nov 2021 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Tryn Stimart, attorney-in-fact
Issuer symbol: ABCL
Transactions as of: 18 Nov 2021
Transactions value $: $3,374,235
Form type: 4
Filing time: 22 Nov 2021, 16:03:00 UTC
Previous filing: 10 Jun 2021
Next filing: 09 Dec 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABCL	Common Shares	Options Exercise	$3.37M	+225K		$15.03	225K	18 Nov 2021	Direct
holding	ABCL	Common Shares						55.8M	18 Nov 2021	See Footnote	F1
holding	ABCL	Common Shares						234K	18 Nov 2021	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABCL	Share option (right to buy)	Options Exercise	$0	-225K	-4.3%	$0.00	4.99M	18 Nov 2021	Common Shares	225K	$2.70	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are held by Thermopylae Holdings Ltd., which is an entity wholly owned by the Reporting Person.
F2	These shares are held by Hankla Family Trust (2019), of which the Reporting Person and his spouse are joint trustees. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his indirect pecuniary interest therein.
F3	The shares subject to such option vest and become exercisable quarterly in substantially equal installments over a four-year period, with the first tranche vested on November 18, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date